Zuellig Pharma and GW Pharmaceuticals sign a partnership agreement in Taiwan
Zuellig Pharma announced a new partnership with GW Pharmaceuticals (GW) to support access to cannabis-based medicines in Taiwan. GW, part of Jazz Pharmaceuticals plc, is a world leader in discovering, developing, and delivering regulatory approved cannabis-based medicines.
As part of GW’s commitment to bringing its medicines to patients and clinicians in Taiwan, it has chosen Zuellig Pharma Taiwan to support appropriate access to GW’s medicines given Zuellig Pharma’s position as the leading medical solutions provider with an end-to-end medical service value chain. From clinical trials, distribution, pharmaceutical commercialisation to patient care services, Zuellig Pharma Taiwan has excellent coverage in pharmaceutical channels, especially in GP and drug stores.
John Chou, Managing Director of Zuellig Pharma Taiwan said, “We are honored to have the opportunity to work with GW Pharmaceuticals when the company decided to enter Asia’s markets. Our company has been present in Taiwan for more than 30 years and has been the business partner of choice for biotechnology companies seeking business expansion in the region. Through this partnership, we hope to make new and innovative therapeutic drugs available for Taiwanese patients, thereby fulfilling Zuellig Pharma’s mission of making healthcare more accessible in Taiwan.”
Joseph Lai, General Manager of ZP Therapeutics, Zuellig Pharma Taiwan shared, “ZP Therapeutics has a deep understanding of the Taiwanese market, healthcare ecosystem and an extensive healthcare commercial team. ZP Therapeutics will continue to deepen our presence in the fields of diabetes, immunology, oncology, vaccines and rare diseases.
“Formally establishing our partnership with Zuellig Pharma in Taiwan underscores our long-term commitment to supporting Taiwanese patients and physicians and furthers GW’s mission to bring innovative medicines to patients with high unmet need” said Chris Tovey, Jazz’s Chief Operating Officer. “Our drive to find solutions for complex medical problems has resulted in the regulatory approval of world-first treatments in a new frontier of medicine.”
About GW Pharma Limited
GW Pharmaceuticals (GW), a subsidiary of Jazz Pharmaceuticals plc, has established a world-leading position in cannabinoid science and medicine. Founded over two decades ago in response to significant unmet patient need, patients remain our key focus and improving their quality of life, our motivation. GW’s pioneering work has led to the regulatory approval of world first, potentially life changing, cannabis-based medicines. Our continued dedication has resulted in the treatment of thousands of patients with our medicines in the UK and around the world. In 2021, GW received the Queens Award for Enterprise in Innovation in recognition of its innovative and ground-breaking work in developing prescription cannabis-based medicines. GW was acquired by Jazz Pharmaceuticals in May 2021.
About Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases—often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines and novel product candidates, from early- to late-stage development, in neuroscience and oncology. Within these therapeutic areas, we are identifying new options for patients by actively exploring small molecules and biologics, and through innovative delivery technologies and cannabinoid science. Jazz is headquartered in Dublin, Ireland and has employees around the globe, serving patients in nearly 75 countries. For more information, please visit www.jazzpharmaceuticals.com and follow @JazzPharma on Twitter.